|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 脂质体阿霉素治疗复发性或晚期子宫平滑肌肉瘤的Ⅱ期临床试验研究:一项GOG研究 | Sutton G. Blessing J. Hanjani P. Kramer P. 李巍 | 2005 | 世界核心医学期刊文摘(妇产科学分册)2005，0，7： | 3 |
| 2 | Brown adipose tissue thermogenesis heats brain and body as part of the brain-coordinated ultradian basic rest-activity cycle显示文摘 | Y. Ootsuka R.C. de Menezes D.V. Zaretsky A. Alimoradian J. Hunt A. Stefanidis B.J. Oldfield W.W. Blessing | 2009 | Neuroscience2009，，2： | 1 |
| 3 | 子宫内膜癌二线化疗药物HMR1275(flavopiridol)的Ⅱ期临床疗效评估:一项妇产科肿瘤组研究 | Grendys Jr.E.C. Blessing J.A. Burger R. Hoff-man J. 刘亦恒 | 2005 | 世界核心医学期刊文摘(妇产科学分册)2005，0，11： | 1 |
| 4 | CORRELATION OF SERUM BRAIN NATRIURETIC PEPTIDE WITH HYPONATREMIA AND DELAYED ISCHEMIC NEUROLOGICAL DEFICITS AFTER SUBARACHNOID HEMORRHAGE显示文摘 | Matthew J. McGirt Robert Blessing Shahid M. Nimjee Allan H. Friedman Michael J. Alexander Daniel T. Laskowitz John R. Lynch | 2004 | Neurosurgery2004，，6： | 1 |
| 5 | On the L D effect for long-rod penetrators显示文摘 | Charles E. Anderson James D. Walker Stephan J. Bless Yehuda Partom | 1996 | International Journal of Impact Engineering1996，，： | 1 |
| 6 | 替拉扎明加顺铂对铂敏感的复发卵巢癌或原发性腹膜癌治疗的二期评估:妇产科肿瘤协作组的研究显示文摘Objectives. To estimate the anti- tumor activity, nature and degree of toxicity of tirapazamine in combination with cisplatin in patients with recurrent platinum- sensitive ovarian or primary peritoneal cancers. Methods. Eligible consenting patients had to have recurrent epithelial ovarian or primary peritoneal carcinoma with measurable disease. Patients were not allowed to have received any additional cytotoxic chemotherapy for management of recurrent or persistent disease, including retreatment with initial chemotherapy regimens. Patients must have been platinum- sensitive, meaning a treatment- free interval of >6 months after response to a platinum- based regimen. The RECIST criteria were used for parameters of response. Tirapazamine was administered at a dose of 390 mg/m2 IV over 2 h followed 1 h later by cisplatin 60 mg/m 2 IV every 3 weeks until disease progression or adverse effects prohibited further therapy. Results. Between June 2001 and February 2004, 65 patients were entered onto this study by 27 institutions; one patient was excluded due to ineligible tumor type. Twenty- six patients (41% ) received six or more cycles of therapy; however, 16 (25% ) received one course of therapy (mainly due to side effects or patient request). There were six (9% ) complete responders and 28 (44% ) partial responders for a total response rate of 53% . Only two patients (3% ) developed increasing disease on this protocol, and response could not be assessed in 18 patients (28% ). The median progression- free and overall survival for all patients is 10.9 and 26.4 months, respectively. The regimen did not cause major hematologic toxicity,however, it did cause frequent constitutional (23% ) and gastrointestinal (mostly nausea/vomiting) (44% ) grade 3 or 4 toxicity. Conclusions. The combination of tirapazamine and cisplatin has definite activity in the treatment of recurrent platinum- sensitive ovarian or primary peritoneal cancer. However, toxicity, primarily non- hematologic,was substantial. Reducing the toxicity of a tirapazamine- platinum combination should be pursued in future trials. | Covens A. Blessing J. BenderD. 吕涛 | 2006 | 世界核心医学期刊文摘(妇产科学分册)2006，2，6： | 1 |
| 7 | Transcranial doppler monitoring and clinical decision-making after subarachnoid hemorrhage显示文摘 | Matthew J. McGirt Robert P. Blessing Larry B. Goldstein | 2003 | Journal of Stroke and Cerebrovascular Diseases2003，，： | 1 |
| 8 | The penetration of steel targets finite in radial extent显示文摘 | David L. Littlefield Charles E. Anderson Yehuda Partom Stephan J. Bless | 1996 | International Journal of Impact Engineering1996，，1： | 1 |
| 9 | 氮烯咪胺、丝裂霉素、阿霉素及顺铂与沙莫司亭治疗平滑肌肉瘤的Ⅱ期试验:妇科肿瘤协作组研究显示文摘Objective. Following a reported 23%response rate (RR) for mitomycin (M), doxorubicin (A), and cisplatin (P) and preliminary data suggesting a superior RR for dacarbazine (D) +MAP +sargramostim, the Gynecologic Oncology Group (GOG) conducted a phase II trial of DMAP +sargramostim in patients with advanced uterine leiomyosarcoma. Methods. Eligibility required measurable disease, a GOG performance score of 0-2, and recovery from surgery/radiotherapy. Treatment consisted of sargramostim 250 μg/m2 SC q 12 h days -6 through -3, followed by D 750 mg/m2 IV over 2 h, M 6 mg/m2 IV, A 40 mg/m2 IV and P 60 mg/m2 IV over 2 h on day 1, followed by sargramostim 250 μg/m2 SC days 2-15. Cycles were repeated q 28 days (if ANC ≥1500/μl and platelets ≥100,000/μl) until disease progression or toxicity prevented further therapy. Doses were to be reduced by 20%for grade 4 neutropenia >7 days or any grade 4 thrombocytopenia and by 10%for a 1-to 2-week treatment delay for myelosuppression. Results. One of 19 patients who entered the study was ineligible. Eighteen patients received a median of 3.5 cycles (range: 1-6 cycles) of therapy. The overall RR was 27.8%(5.6%complete and 22.2%partial responses). Percent of patients with grade 3 or 4 toxicities included 78%neutropenia, 94%thrombocytopenia, 61%anemia, 44%GI, 28%infection, and 17%azotemia. Conclusions. DMAP +sargramostim produced a 27.8%RR, but its complexity and toxicity precluded further investigation, and the study was closed after the first stage of accrual. | Long III H.J. Blessing J.A. Sorosky J. 朱晓明 | 2006 | 世界核心医学期刊文摘(妇产科学分册)2006，0，2： | 0 |
| 10 | 拓扑替康应用于子宫癌肉瘤的二期评价:一项妇科肿瘤组研究 | Miller D.S. Blessing J.A. Schilder J. 张丽娟 | 2005 | 世界核心医学期刊文摘(妇产科学分册)2005，0，12： | 0 |
| 11 | 每4周40mg/m^2脂质体阿霉素治疗子宫内膜癌的Ⅱ期试验:一项妇科肿瘤组研究 | Homesley H.D. Blessing J.A. Sorosky J. 刘亦恒 | 2005 | 世界核心医学期刊文摘(妇产科学分册)2005，0，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员